| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3006859 | Progress in Cardiovascular Diseases | 2012 | 10 Pages |
Abstract
Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mark V. Sherrid, Milla Arabadjian,